Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Among authors: scott c. Diabetes Care. 2022 Apr 1;45(4):888-897. doi: 10.2337/dc21-1944. Diabetes Care. 2022. PMID: 35061867 Free PMC article. Clinical Trial.
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Amod A, Marre M, Joseph A, Lage A, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Among authors: scott c. Diabetes Obes Metab. 2022 Jan;24(1):125-134. doi: 10.1111/dom.14558. Epub 2021 Oct 11. Diabetes Obes Metab. 2022. PMID: 34580995 Free PMC article. Clinical Trial.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, Pitt B, Kolkhof P, Scott C, Lawatscheck R, Wilson DJ, Bakris GL; FIDELIO-DKD Investigators. Agarwal R, et al. Among authors: scott c. J Am Soc Nephrol. 2022 Jan;33(1):225-237. doi: 10.1681/ASN.2021070942. Epub 2021 Nov 3. J Am Soc Nephrol. 2022. PMID: 34732509 Free PMC article. Clinical Trial.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Agarwal R, et al. Among authors: scott c. Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336. Nephrol Dial Transplant. 2022. PMID: 34850173 Free PMC article. Clinical Trial.
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Rossing P, Filippatos G, Agarwal R, Anker SD, Pitt B, Ruilope LM, Chan JCN, Kooy A, McCafferty K, Schernthaner G, Wanner C, Joseph A, Scheerer MF, Scott C, Bakris GL; FIDELIO-DKD Investigators. Rossing P, et al. Among authors: scott c. Kidney Int Rep. 2021 Oct 14;7(1):36-45. doi: 10.1016/j.ekir.2021.10.008. eCollection 2022 Jan. Kidney Int Rep. 2021. PMID: 35005312 Free PMC article.
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, Anker SD; FIDELIO-DKD Investigators. Filippatos G, et al. Among authors: scott c. Eur J Heart Fail. 2022 Jun;24(6):996-1005. doi: 10.1002/ejhf.2469. Epub 2022 May 19. Eur J Heart Fail. 2022. PMID: 35239204 Free PMC article. Clinical Trial.
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rossing P, Scott C, Gay A, Agarwal R. Green JB, et al. Among authors: scott c. Nephrol Dial Transplant. 2023 Mar 31;38(4):894-903. doi: 10.1093/ndt/gfac198. Nephrol Dial Transplant. 2023. PMID: 35700142 Free PMC article. Clinical Trial.
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
McGill JB, Agarwal R, Anker SD, Bakris GL, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, Caramori ML, Brinker M, Joseph A, Lage A, Lawatscheck R, Scott C, Rossing P; FIDELIO-DKD and FIGARO-DKD investigators. McGill JB, et al. Among authors: scott c. Diabetes Obes Metab. 2023 Jun;25(6):1512-1522. doi: 10.1111/dom.14999. Epub 2023 Feb 26. Diabetes Obes Metab. 2023. PMID: 36722675
4,420 results